The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2020 | The future of CLL treatment: chemotherapy and targeted inhibitors
Catherine Wu, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the future of treatment in chronic lymphocytic leukemia (CLL). In the past chemotherapy and individual target inhibitors have been explored. Now the combination of both is being investigated for effect tumour eliminating therapies with limited toxicity. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.
Disclosures
Catherine Wu, MD, holds equity in BionTech, Inc; and receives research funding from Pharmacyclics.
